Beat The Denominator

Buy Meta Platforms (META) as it trades below $550, offering an attractive entry point into the cheapest Magnificent Seven stock while short-term legal headlines mask its strong 23% revenue growth and long-term AI monetization potential.

Accumulate shares of AppLovin (APP) on its 50% pullback to capture upside from its high 79% EBITDA margins as the company expands its digital advertising engine beyond mobile gaming into e-commerce.

Invest in IREN (IREN) for discounted exposure to the AI cloud infrastructure space, taking advantage of an approximate 40% forward valuation discount compared to peers like Nebius.

Purchase shares of Sezzle (SEZL) after its 33% drop to gain profitable, high-growth exposure to the Buy Now, Pay Later (BNPL) sector at a significant valuation discount relative to Affirm (AFRM).

Zoom Video Communications (ZM) offers an asymmetric upside opportunity ahead of a rumored October IPO for Anthropic, where its roughly 1% stake could unlock an estimated 80% gain for the stock. ZM simultaneously provides strong downside protection for value-focused investors thanks to a low 17 P/E ratio and a massive $7.7 billion cash cushion. If Anthropic goes public at the anticipated $2 trillion valuation, this landmark liquidity event will serve as an immediate repricing catalyst for its major corporate shareholders. For a lower-risk approach, Amazon.com (AMZN) provides conservative Anthropic exposure through its 15% stake, offering a steady 13% to 15% boost to its overall valuation. Investors seeking broader mega-cap AI exposure outside of private proxy plays should prioritize NVIDIA (NVDA) over Alphabet (GOOGL) due to its superior growth-adjusted valuation.

Watch for a buying opportunity in MicroStrategy (MSTR) around its expected $5.0 billion to $5.5 billion cash reserve update on Monday morning, as the conclusion of its equity dilution could trigger a sharp catch-up rally. Income-oriented investors should consider MicroStrategy Preferreds (STRC), which offers an estimated 12% yield and capital appreciation potential as it trades up toward its key $100 par value from $96. While Bitcoin (BTC) recently surged past $78,000, short-term traders should prepare for potential profit-taking pullbacks into the $63,000 to $77,000 range before institutional demand via funds like the iShares Bitcoin Trust (IBIT) drives the next move. Broader tech and high-growth asset momentum will likely stay range-bound until NVIDIA (NVDA) delivers market-wide direction with its earnings release on Wednesday, August 26th after the closing bell. Finally, manage risk into Federal Reserve Chair Jerome Powell's address at the Jackson Hole Symposium on Friday at 10:00 AM Eastern, which serves as a major macro catalyst for interest rates and digital credit assets.

Following a recent 39% political-headline rally, investors holding Hyperliquid (HYPE) should consider selling covered calls to capture high option premiums and hedge against a near-term price pullback.

For long-term growth, Hyperliquid (HYPE) remains fundamentally strong because 99% of its network fees are used to buy back and burn tokens, creating sustained structural demand.

Investors should avoid chasing the recent 52% momentum spike in Purr (PURR), as rapid multi-day gains present a high risk of an immediate market correction.

When evaluating Layer-1 decentralized finance (DeFi) assets like Solana (SOL), prioritize tokens with aggressive fee-capture mechanisms over platforms that simply generate high gross transaction volume.

For core crypto exposure, accumulate Bitcoin (BTC) and the iShares Bitcoin Trust (IBIT) during price consolidations around $73,000 rather than chasing sharp rallies against elevated 10-Year US Treasury Yields.

Long-term investors holding MicroStrategy (MSTR) around $112 should anticipate temporary performance lag relative to Bitcoin while the company actively sells shares to build its $5 billion cash reserve.

Income-focused investors can target MicroStrategy Stretch (STRC) at $95.25 to lock in an effective 12.5% yield alongside roughly 5% capital appreciation potential toward its $100 par value.

Alternatively, Strive Preferred (SATA) offers an attractive, steady cash-flow trade at its $100 par value by delivering a 13% annual dividend distributed daily to support parent company Strive Asset Management (ASST).

Meta Platforms (META) represents a prime mega-cap value opportunity as short-term legal risks are overblown, offering an attractive long-term price target between $800 and $900.

In semiconductors, Micron Technology (MU) is an exceptional value trade trading at just 5x forward earnings, fully derisked by long-term customer prepayments for high-demand AI memory.

NVIDIA (NVDA) remains an essential core holding for artificial intelligence, trading cheaper on a growth-adjusted basis than most mega-cap peers with a long-term trajectory toward a $10 trillion valuation.

Investors looking for high-growth software should capitalize on the recent 50% pullback in AppLovin (APP), which is significantly oversold despite market-leading profit efficiency.

For aggressive investors seeking leveraged exposure to AI data center infrastructure, IREN (IREN) offers 80% to 100% upside potential, while Cipher Mining (CIFR) presents a high-upside recovery target of $15 to $30.

Investors looking to capitalize on expanding market liquidity should target Bitcoin (BTC), or use MicroStrategy (MSTR) as a high-beta leveraged proxy to capture outsized upside during aggressive rallies. Consider accumulating Hyperliquid (HYPE) to benefit from its industry-leading 99% fee-burn mechanics and potential expansion into the U.S. market. Telehealth leader Hims & Hers Health (HIMS) remains a top-conviction stock poised to deliver strong returns as broader risk-on sentiment expands. A massive 181% surge in Moderna (MRNA) marks a turning point for the beaten-down biotech sector, signaling asymmetric upside for innovative healthcare plays during monetary easing cycles. In AI infrastructure, execute a catch-up trade by rotating capital away from extended names like Nebius Group (NBIS) and into deeply discounted peers like Iris Energy (IREN) and Cipher Mining (CIFR).

Consider buying the recent 10% pullback in Meta Platforms (META), as sharp valuation compression driven by overblown regulatory fears creates an attractive entry point.

Accumulate Hims & Hers Health (HIMS) on current market weakness to capture massive long-term upside from off-patent GLP-1 peptides ahead of the 2029–2030 patent expirations.

Take advantage of steep tech dips to build positions in AI infrastructure providers like Nebius Group (NBIS) and Iris Energy (IREN), which hold a competitive edge by owning their physical GPUs rather than acting as basic data center landlords.

Add high-performing growth stocks such as SoFi Technologies (SOFI), Sea Limited (SE), and Zeta Global (ZETA) to your portfolio, as their recent price drops are driven by broad macro volatility rather than their strong Q2 operational performance.

Prioritize direct spot Bitcoin (BTC) exposure over mining equities like Marathon Digital (MARA) or Cipher Mining (CIFR), as public crypto stocks remain burdened by equity market sell-offs and ongoing share dilution.

Investors should look to buy IREN (IREN) ahead of its late-August earnings catalyst, as its official NVIDIA partnership and massive valuation discount offer an attractive entry point into Neocloud infrastructure. Conversely, consider taking profits on Nebius Group (NBIS) around the $270 level, where the stock has become overextended relative to industry peers. The headline-driven pullback in Meta Platforms (META) presents a compelling buying opportunity, establishing it as the most attractively valued company among the Magnificent Seven. Backed by resilient growth across Instagram and WhatsApp, META is well-positioned for a rebound toward $600+ as near-term litigation noise clears.

Investors should anticipate range-bound price action in Bitcoin (BTC) during the current low-liquidity seasonal lull, targeting late August and September for a potential institutional volume breakout. Approach MicroStrategy (MSTR) strictly as a patient, leveraged proxy for Bitcoin, as recent stock dilution offers limited upside from corporate balance-sheet moves alone. For income-focused investors, Strategy Preferred Stock (STRC) provides a secure dividend opportunity backed by MicroStrategy's $4.80 billion cash reserve, which secures three years of payout coverage. Meaningful price appreciation for STRC will require declining interest rates, specifically a drop in the 10-year US Treasury yield, paired with broader crypto market strength. Until market liquidity rebounds in the fall, short-term speculative capital is likely to remain concentrated in alternative themes like Artificial Intelligence (AI) rather than digital assets.

Do not chase Nebius (NBIS) at its current all-time high due to extreme short-term volatility, but keep it on your radar for a very long-term position. Wait for aggressive market sell-offs or bear attacks to scoop up NBIS at a discount, as the stock has a history of overcorrecting. Use the strong execution of Micron (MU) as a benchmark to evaluate how effectively infrastructure suppliers handle early customer prepayments. Closely monitor the deployment timeline of the 5,000-megawatt capacity pipeline for NBIS through 2027 to ensure smooth operational growth. Finally, watch developments in the autonomous vehicle sector—led by Tesla (TSLA)—to accurately gauge the hidden, undervalued potential of the AV Ride subsidiary.

Capitalize on the recent post-earnings dip to buy shares of Hims & Hers Health (HIMS) around $29.50, viewing this pullback as an attractive entry point for a long-term holding.

The company is experiencing rapid scaling driven by strong subscriber growth and expanding high-margin specialties like testosterone replacement therapy.

Look for an upcoming catalyst this fall with the launch of new peptide offerings supported by their newly acquired U.S. manufacturing facility.

The business model benefits from a cash-pay system that bypasses insurance hurdles and leverages artificial intelligence for personalized healthcare treatments across its 3 million subscribers.

Investors should overlook short-term gross margin compression and GAAP net losses, recognizing them as strategic growth investments for this subscription-based healthcare platform.

Anticipate near-term downward or sideways pressure on MicroStrategy Inc. (MSTR) as the company continues diluting common stock to reach its rumored $5 billion USD cash reserve goal.

Investors bullish on Bitcoin should note that MSTR is currently prioritizing balance sheet safety and STRC support over aggressive new crypto accumulation.

Monitor STRC for a continued recovery toward its target price of $100, supported by management's recent buybacks and proactive market signaling.

Recognize that buying MSTR right now means tying your capital to a defensive corporate strategy during a volatile period for cryptocurrency markets.

Only enter MSTR positions if you are comfortable with potential equity dilution while waiting for Bitcoin prices to break out from the $65,000 range.

Wait to buy Hims & Hers Health (HIMS) at $31 until after earnings, targeting a 20% narrative-driven pullback to accumulate shares at a discount.

Capitalize on Nebius (NBIS) trading at $187 by treating short-seller pressure as a buying opportunity for this high-growth AI infrastructure play with a $51 billion pipeline.

Exercise patience with Nebius (NBIS) by avoiding pre-earnings bets and waiting for short-term volatility to secure better entry points.

Target CoreWeave (COREW), valued at an $82 billion market cap, as a top pure-play NeoCloud candidate if a broader market pullback creates a 30% discount.

Accumulate Bitcoin (BTC) near the $65,000 support level as a stabilizing foundation for broader crypto and risk asset recovery.

Target a breakout toward $70,000 to $80,000 to capitalize on high-beta upside for correlated equities like MicroStrategy (MSTR).

Use MicroStrategy (MSTR) as an amplified proxy for Bitcoin, keeping a close eye on its net asset value multiple to time your entries effectively.

Buy STRC below its $100 par value to lock in a compelling 12% yield that becomes increasingly attractive as Treasury yields decline.

Consider Seta trading near $99 for its higher 13% yield and simpler balance sheet as it rapidly approaches par value ahead of peers.